Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
Ella Grilz,
Oliver Königsbrügge,
Florian Posch,
Manuela Schmidinger,
Robert Pirker,
Irene M. Lang,
Ingrid Pabinger,
Cihan Ay
Affiliations
Ella Grilz
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria
Oliver Königsbrügge
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria
Florian Posch
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria;Division of Oncology, Department of Internal Medicine, Medical University of Graz, Austria
Manuela Schmidinger
Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria
Robert Pirker
Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria
Irene M. Lang
Clinical Division of Cardiology, Department of Medicine II, Medical University of Vienna, Austria
Ingrid Pabinger
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria
Cihan Ay
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria
In contrast to venous thromboembolism, little is known about arterial thromboembolism in patients with cancer. The aim of this study was to quantify the risk and explore clinical risk factors of arterial thromboembolism in patients with cancer, and investigate its potential impact on mortality. Patients with newly-diagnosed cancer or progression of disease after remission were included in a prospective observational cohort study and followed for two years. Between October 2003 and October 2013, 1880 patients (54.3% male; median age 61 years) were included. During a median follow up of 723 days, 48 (2.6%) patients developed arterial thromboembolism [20 (41.7%) myocardial infarction, 16 (33.3%) stroke and 12 (25.0%) peripheral arterial events], 157 (8.4%) developed venous thromboembolism, and 754 (40.1%) patients died. The cumulative 3-, 6-, 12-, and 24-month risks of arterial thromboembolism were 0.9%, 1.1%, 1.7%, and 2.6%, respectively. Male sex (subdistribution hazard ratio=2.9, 95%CI: 1.5-5.6; P=0.002), age (subdistribution hazard ratio per 10 year increase=1.5, 1.2-1.7; P